| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 150, 805-814, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
S Krajewski, M Krajewska, J Ehrmann, M Sikorska, B Lach, J Chatten and JC Reed
Burnham Institute, Cancer Research Center, La Jolla, California 92037, USA.
The expression of Bcl-2, Bcl-X, Mcl-1, and Bax was examined by immunohistochemical methods in 93 tumors of nervous system origin, including 49 gliomas (30 astrocytomas and 19 glioblastoma multiforme (GMs)), 16 medulloblastomas (MBs), 19 neuroblastomas (NBs; 9 undifferentiated and 10 differentiated), and 9 miscellaneous neuroectodermal neoplasms. Among the 49 gliomas, immunopositivity (defined as > or = 10%) was observed for Bcl-2 in 45 (92%), Bcl-X in 48 (98%), Mcl-1 in 49 (100%), and Bax in 48 (98%) of 49 specimens. In 11 (37%) of 30 astrocytomas (WHO grades I to III), the tumor specimens were composed predominantly of malignant cells with strong-intensity Bcl-2 immunostaining, whereas none of the 19 GMs (WHO grade IV) exhibited strong-intensity Bcl-2 immunoreactivity (P = 0.001). Similarly, Mcl-1 immunointensity was strong in 15 (50%) of 30 astrocytomas, compared with only 2 (11%) of 19 GMs (P = 0.005). The percentage of Mcl-1-immunopositive tumor cells was also higher in astrocytomas than GMs (P < 0.002). Thus, contrary to a priori expectations, the expression of the anti-apoptotic proteins Bcl-2 and Mcl-1 was significantly higher in astrocytomas than in GMs. Of the 16 MBs, immunopositivity was found for Bcl-2 in 4 (25%), Bcl-X in 9 (56%), Mcl-1 in 8 (50%), and Bax in 16 (100%) of the cases. The intensity of immunostaining was strong for Bcl-2 in only 1 (6%) specimen, for Bcl-X in 3 (19%), and for Mcl-1 in 2 (12.5%), in contrast to Bax immunostaining, which was strong in 12 (75%) tumors. Significantly higher percentages of Bax-immunopositive tumor cells were also found in MBs, compared with Bcl-2, Bcl-X, and Mcl-1 (P < 0.0001). All 19 NBs were immunopositive for Bcl-2, Bcl-X, Mcl-1, and Bax. Higher percentages of Bcl-X- and Mcl-1-immunopositive tumor cells were observed in well differentiated tumors (P = 0.04 and 0.004, respectively). The intensity of Mcl-1 immunostaining was also generally higher in differentiated than undifferentiated NBs (strong immunointensity in 7 of 10 versus 0 of 9; P = 0.002). Conversely, strong-intensity Bax immunostaining was associated with undifferentiated histology (5 of 9 (56%) versus 1 of 10 (10%); P = 0.03). Taken together, these findings begin to delineate trends in the regulation of the relative levels of the Bcl-2 family proteins, Bcl-2, Bcl-X, Mcl-1, and Bax in gliomas, MBs, NBs, and some of their histological subtypes. The suggestion that expression of some of these Bcl-2 family genes may be differentially regulated in association with tumor progression and differentiation provides insights into the diverse biology and clinical behavior of these tumors of nervous system origin.
This article has been cited by other articles:
 |
|
 |
|
  E. A. Beierle, N. A. Massoll, J. Hartwich, E. V. Kurenova, V. M. Golubovskaya, W. G. Cance, P. McGrady, and W. B. London Focal Adhesion Kinase Expression in Human Neuroblastoma: Immunohistochemical and Real-time PCR Analyses Clin. Cancer Res., June 1, 2008; 14(11): 3299 - 3305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Giorgini, D. Trisciuoglio, C. Gabellini, M. Desideri, L. Castellini, C. Colarossi, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression Mol. Cancer Res., August 1, 2007; 5(8): 761 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Tran, W. S. McDonough, B. A. Savitch, T. F. Sawyer, J. A. Winkles, and M. E. Berens The Tumor Necrosis Factor-like Weak Inducer of Apoptosis (TWEAK)-Fibroblast Growth Factor-inducible 14 (Fn14) Signaling System Regulates Glioma Cell Survival via NF{kappa}B Pathway Activation and BCL-XL/BCL-W Expression J. Biol. Chem., February 4, 2005; 280(5): 3483 - 3492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. H. Bigelow, N. S. Chari, A. B. Unden, K. B. Spurgers, S. Lee, D. R. Roop, R. Toftgard, and T. J. McDonnell Transcriptional Regulation of bcl-2 Mediated by the Sonic Hedgehog Signaling Pathway through gli-1 J. Biol. Chem., January 9, 2004; 279(2): 1197 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Watanabe, Y Oda, S Tamiya, K Masuda, and M Tsuneyoshi Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components J. Clin. Pathol., August 1, 2001; 54(8): 631 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Strik, M Deininger, J Streffer, E Grote, J Wickboldt, J Dichgans, M Weller, and R Meyermann BCL-2 Family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy J. Neurol. Neurosurg. Psychiatry, December 1, 1999; 67(6): 763 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bairey, Y. Zimra, M. Shaklai, E. Okon, and E. Rabizadeh Bcl-2, Bcl-X, Bax, and Bak Expression in Short- and Long-Lived Patients with Diffuse Large B-Cell Lymphomas Clin. Cancer Res., October 1, 1999; 5(10): 2860 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Terui, M. Ikeda, H. Tomizuka, T. Kasahara, T. Ohtsuki, M. Uwai, M. Mori, T. Itoh, M. Tanaka, M. Yamada, et al. Activated Endothelial Cells Induce Apoptosis in Leukemic Cells by Endothelial Interleukin-8 Blood, October 15, 1998; 92(8): 2672 - 2680. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
